CalciMedica (NASDAQ:CALC) Stock Rating Upgraded by Wall Street Zen

CalciMedica (NASDAQ:CALC) was upgraded by equities research analysts at Wall Street Zen to a “sell” rating in a report issued on Saturday.

Several other equities research analysts have also issued reports on CALC. Guggenheim began coverage on shares of CalciMedica in a research report on Thursday. They issued a “buy” rating for the company. HC Wainwright reiterated a “neutral” rating on shares of CalciMedica in a research note on Wednesday, July 29th. Weiss Ratings cut shares of CalciMedica from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, August 13th. Finally, UBS Group restated a “neutral” rating on shares of CalciMedica in a research note on Thursday, August 13th. Two research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, CalciMedica presently has an average rating of “Hold” and a consensus target price of $10.00.

CalciMedica Price Performance

CALC stock opened at $0.57 on Friday. The stock has a 50-day moving average price of $0.78 and a two-hundred day moving average price of $0.71. CalciMedica has a 12-month low of $0.46 and a 12-month high of $7.20. The company has a current ratio of 5.58, a quick ratio of 5.58 and a debt-to-equity ratio of 1.67. The company has a market cap of $19.56 million, a PE ratio of -0.42 and a beta of 0.91.

CalciMedica (NASDAQ:CALC) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.17). As a group, research analysts predict that CalciMedica will post -1.05 EPS for the current year.

Insider Transactions at CalciMedica

In related news, Director Fred A. Middleton acquired 248,972 shares of CalciMedica stock in a transaction on Thursday, June 25th. The shares were purchased at an average cost of $0.80 per share, for a total transaction of $199,177.60. Following the purchase, the director directly owned 1,063,272 shares of the company’s stock, valued at $850,617.60. The trade was a 30.57% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 28.25% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On CalciMedica

Hedge funds and other institutional investors have recently modified their holdings of the stock. Cetera Investment Advisers raised its stake in shares of CalciMedica by 33.1% in the 2nd quarter. Cetera Investment Advisers now owns 36,385 shares of the company’s stock valued at $58,000 after purchasing an additional 9,045 shares in the last quarter. 180 Wealth Advisors LLC grew its stake in CalciMedica by 297.2% in the first quarter. 180 Wealth Advisors LLC now owns 126,500 shares of the company’s stock worth $68,000 after purchasing an additional 94,650 shares in the last quarter. Renaissance Technologies LLC grew its stake in CalciMedica by 45.0% in the first quarter. Renaissance Technologies LLC now owns 128,075 shares of the company’s stock worth $69,000 after purchasing an additional 39,775 shares in the last quarter. Jane Street Group LLC bought a new stake in CalciMedica in the fourth quarter valued at about $127,000. Finally, Envestnet Asset Management Inc. increased its holdings in CalciMedica by 58.2% in the second quarter. Envestnet Asset Management Inc. now owns 93,433 shares of the company’s stock valued at $149,000 after buying an additional 34,386 shares during the last quarter.

About CalciMedica

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.